A common side effect of antipsychotic treatment with atypical neuroleptics is a significant weight gain. This stabilizes in the short to medium term but with clozapine often continues beyond the first year leading to weight gains of up to 20-30 kg. 1 This increase in weight is significantly correlated with clinical improvements, but the causes of treatmentemergent weight gain in schizophrenic patients are currently unknown. It is assumed that the perception of satiety is impaired, as patients experience a lower suppression of appetite after meals when consuming atypical neuroleptics. 1 Supporting this hypothesis, clozapine has been found to increase serum leptin levels within days after starting treatment.
2 Unfortunately, strict food reduction shows little success indicating that central pathways rather than peripheral actions of atypical neuroleptics or their mediators are involved in weight gain. Evaluation of the body composition revealed an increase in body fat under antipsychotic treatment with atypical antipsychotic drugs, 3 and blockade of serotonin and histamine receptors by these drugs was previously shown to be associated with weight gain. 4 In addition to enhanced lipid accumulation in adipocytes, enhanced differentiation of preadipocytes can increase body fat. Our study addresses the question of whether clozapineinduced weight gain is based on neo-formation of adipose tissue from precursor cells. All experiments had been approved by the Ethical Committee of the Aachen University of Technology.
Preadipocytes were isolated from human abdominal subcutaneous adipose tissue samples (n = 7) and cultured in Dulbecco's modified Eagle's medium (DMEM)/ Ham's F12 (F12) until confluence.
5 Adipogenic conversion was then promoted for 14 days by changing medium to fetal calf serum-free DMEM/F12, supplemented with 66 nM insulin, 100 nM dexamethasone, 0.5 mM isobutylmethylxanthine (IBMX), 0.1 mg ml À1 pioglitazone, 1 nM triiodo-L-thyronine and 10 mg ml À1 human transferrin. After 5 days of incubation, medium was used as described before but without IBMX and pioglitazone for 9 more days. Clozapine (5-50 mM) was added for the first 5 days during differentiation. The mood-stabilizing drug lithium chloride (2 mM) was used as negative control. Cells were counted and fluorescence microscopy was applied to detect apoptotic cells stained for 5 min by Hoechst 33342 (8 mg/ml). To evaluate preadipocyte differentiation on the molecular level, the activity of glycerol 3-phosphate dehydrogenase (GPDH), a molecular key marker of adipogenic conversion, was determined after 14 days by measuring enzyme activity 5 and normalizing for protein content and cell number. To confirm adipocyte maturation from progenitor cells morphologically, Oil Red O staining was applied.
Neither apoptosis nor proliferation was affected by clozapine treatment. Preadipocytes treated with clozapine (5 mM) showed a significantly higher percentage of differentiated cells (126712%) compared to controls (100%) (Figure 1a ). LiCl as well as the typical neuroleptic drug haloperidol (data not shown) did not increase GPDH-activity, but rather inhibited differentiation to a minor extent. Oil red staining of the cells confirmed these results (Figure 1b 6, 7 demonstrated that the balance between proliferation and differentiation of adipocyte progenitor cells is regulated by intracellular oxidative stress. They reported that propofol, an anesthetic agent, that inhibits mitochondrial respiration and reduces oxidative stress, significantly increased preadipocyte differentiation by 125710%. Similar to propofol 6 and beside its receptor-mediated effects, clozapine is known to induce mitochondrial superoxide release, previously detected in neutrophils of patients under clozapine treatment, 8 and also seen in clozapinetreated preadipocytes. Additionally, the phenolic moiety of both molecules scavenges radicals.
9 Dalla Libera et al. 10 demonstrated that the antioxidant properties of clozapine are particularly effective in the hydrophobic environment of membranes and fat tissue. Furthermore, clozapine accumulates in adipose tissue (Novartis, personal communication), where the concentration of the drug might be even higher than the 5 mM used in this study.
In line with the results of Carriere 6,7 and Galinier et al.
11 who found obesity associated with reduced oxidative stress, we propose that the reduced redox state under clozapine-and propofol-treatment favours preadipocyte differentiation probably independent from receptor-activated pathways. Therefore longterm clozapine-treatment causes a steady proliferation of preadipocytes and neoformation of adipocytes leading to permanent weight gain.
Six degrees of separation: on the prior probability that schizophrenia susceptibility genes converge on synapses, glutamate and NMDA receptors It has been proposed that schizophrenia susceptibility genes converge upon synapses 1,2 and glutamate, [1] [2] [3] [4] impacting particularly on N-methyl-D-aspartate receptor (NMDAR) signalling. 1, 2, 4 One of the problems with the proposition concerns the prior probability that it is true. Much of the genome is expressed in the brain, many genes encode synaptic proteins, 5 many synapses utilize glutamate, 6 and most of these contain NMDARs. 7 Thus, the proposition is inherently weak, as any randomly selected group of genes is likely to include a large fraction that converge on synapses, glutamate and NMDARs. This is akin to the 'six degrees of separation', postulated by Karinthy in 1929 regarding the relatedness of individuals, and recently extended not only to computational science and
